Studies on type II progesterone receptor in MCF-7 cells
Related Experiment Videos
D E Saunders1, C Christensen, S C Brooks
1Department of Biochemistry, Wayne State University School of Medicine, Detroit, MI 48201.
Abstract:
These experiments demonstrate for the first time the existence of a Type II progesterone receptor (RpII) in MCF-7 human breast cancer cells. RpII was shown to have a lower affinity for tritiated progesterone ([3H]Pg) (Kd greater than or equal to 13 nM) than classical Rp (Kd less than or equal to 3 nM). RpII was detected by cytosolic, nuclear, and whole cell assays of MCF-7 cells. Scatchard analysis of [3H]Pg binding data revealed that classical Rp but not RpII could be recompartmentalized from the cytosolic to the nuclear pool by treating cells 1 h at 37 degrees C with 1 microM Pg. RpII levels were shown to be increased more than two-fold by growing MCF-7 cells for 4 days in 10 nM estradiol (E2) plus 100 nM Pg when compared to either untreated cells or to cells treated with only E2.
Insights
Scientists discovered a new progesterone receptor (RpII) in breast cancer cells, distinct from the classical type. This novel receptor shows different binding affinities and cellular localization, offering new insights into hormone action in cancer.
Area of Science:
- Endocrinology
- Molecular Biology
- Cancer Research
Background:
- Progesterone receptors are critical in regulating cellular functions, particularly in hormone-responsive tissues like the breast.
- Understanding the different types and behaviors of progesterone receptors is essential for developing targeted cancer therapies.
Purpose of the Study:
- To identify and characterize a potential Type II progesterone receptor (RpII) in MCF-7 human breast cancer cells.
- To compare the binding affinity and cellular localization of RpII with the classical progesterone receptor (Rp).
Main Methods:
- Utilized radioligand binding assays with tritiated progesterone ([3H]Pg) to quantify receptor levels.
- Employed Scatchard analysis to determine binding affinities (Kd) and receptor characteristics.
- Performed cytosolic, nuclear, and whole-cell assays to assess receptor localization.
- Investigated receptor recompartmentalization and expression levels following hormonal treatments (estradiol and progesterone).
Main Results:
- Demonstrated the existence of RpII in MCF-7 cells, exhibiting lower progesterone affinity (Kd ≥ 13 nM) compared to classical Rp (Kd ≤ 3 nM).
- RpII was detected in cytosolic, nuclear, and whole-cell fractions.
- Unlike classical Rp, RpII did not readily recompartmentalize to the nucleus upon progesterone stimulation.
- RpII expression levels significantly increased (over two-fold) after prolonged exposure to both estradiol (E2) and progesterone (Pg).
Conclusions:
- MCF-7 cells possess a distinct Type II progesterone receptor (RpII) with unique biochemical properties.
- RpII's differential binding affinity and localization suggest a potentially separate functional role in breast cancer cells.
- The upregulation of RpII by E2 and Pg indicates its involvement in hormone-driven breast cancer progression.